US 12,441,811 B2
Compositions and methods for treating serpin B13 disorders
Jan Czyzyk, Minneapolis, MN (US)
Assigned to REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
Appl. No. 17/633,012
Filed by REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
PCT Filed Aug. 3, 2020, PCT No. PCT/US2020/044729
§ 371(c)(1), (2) Date Feb. 4, 2022,
PCT Pub. No. WO2021/026064, PCT Pub. Date Feb. 11, 2021.
Claims priority of provisional application 63/040,356, filed on Jun. 17, 2020.
Claims priority of provisional application 62/883,443, filed on Aug. 6, 2019.
Prior Publication US 2022/0267468 A1, Aug. 25, 2022
Int. Cl. C07K 16/38 (2006.01)
CPC C07K 16/38 (2013.01) [C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 15 Claims
 
1. An isolated antibody or antigen-binding fragment thereof that binds to OVA-serine proteinase inhibitor (serpin) B 13 and comprises a heavy chain, wherein the heavy chain comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, and a light chain, wherein the light chain comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein:
(i) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:26, SEQ ID NO:60, SEQ ID NO:70 or SEQ ID NO:80,
(ii) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO:4, SEQ ID NO:27, SEQ ID NO:61, SEQ ID NO:71 or SEQ ID NO:81,
(iii) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:6, SEQ ID NO:28, SEQ ID NO:62, SEQ ID NO:72 or SEQ ID NO:82,
(iv) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO:8, SEQ ID NO:29, SEQ ID NO:63, SEQ ID NO:73 or SEQ ID NO:83,
(v) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO:10, SEQ ID NO:64, SEQ ID NO:74 or SEQ ID NO:84, and
(vi) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:12, SEQ ID NO:65, SEQ ID NO:75 or SEQ ID NO:85.